BioCryst Pharmaceuticals | BCRX - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Chugai Pharma JPY 426.6B 29.83B 2025-12
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
DBV Technologies USD 194.17M 124.33M 2025-12
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novavax USD 228.36M 12.27M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03